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Tilorone, 100 mgikg. was given once a week to two groups of NZBiNZW mice: young 
mice aged 3 months without overt disease. and g-month-old mice with established au- 
toimmune disease. Young treated animals died prematurely with severe glomerulone- 
phritis and vasculitis, but lifespans were not shortened in old treated mice. Thymic at- 
rophy was common in treated animals. Tilorone therapy did not affect autoantibody 
levels: nevertheless. terminal C, values were decreased significantly in young treated 
mice. Although interferon activity was detected in sera from young treated mice. it 
provided no protection from spontaneous autoimmune disease. Tilorone-induced sup- 
pression of cell-mediated immunity may have caused accelerated disease and premature 
death in NZB/NZW mice. 
INTRODUCTION 
First-generation hybrid offspring of New Zealand black (NZB) and New Zea- 
land white (NZW) mice spontaneously develop heterogeneous antinuclear an- 
tibodies (ANA), specific antibodies to DNA (anti-DNA), and immune-complex 
glomerulonephritis (1). These animals carry C-type viral particles (2). It has been 
postulated that the endogenous viruses stimulate autoantibody production in the 
host animals, which are immunologically hyperresponsive to nucleic acid antigens 
(3). The current study was designed to investigate the effects of a potent inducer of 
interferon on the course of autoimmune disease in NZB/NZW mice. Tilorone 
(2,7-bis[(diethylamino)ethoxy]fluoren-9-one dihydrochloride) is a low- 
molecular-weight aromatic amine with activity against RNA- and DNA-containing 
viruses in mice (4). This drug was fed to young NZB/NZW mice and to older 
NZB/NZW mice with established autoimmune disease. When treated mice were 
tested 6 months and 8 months after the study began, interferon activity was 
detected in their sera. Nevertheless, in the young treated animals autoantibody 
levels increased, serum complement levels fell, and severe vasculitis and 
glomerulonephritis caused premature death. 
’ This study was supported by Grant CA 13297 from the National Cancer Institute. Special Fellow- 
ship AM 44077 from the NIH. USPHS. and a Research Grant from the Michigan Chapter of the 
Arthritis Foundation. 
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MATERIALS AND METHODS 
Treatment Protocol 
The origin and maintenance of NZB and NZW mouse colonies and breeding of 
hybrid NZB/NZW mice in the Rackham Arthritis Research Unit have been de- 
scribed (5). Tilorone was obtained from Merrell National Laboratories, Cincin- 
nati, Ohio. Tilorone, 100 mg/kg in 0.25 ml of distilled water, was given by gavage 
once a week to 15 young female NZB/NZW mice aged 4 to 16 weeks (mean 11 
weeks). Fifteen female littermate mice serving as controls received distilled water 
by gavage. To determine the effects of therapy in animals with established dis- 
ease, 15 old treated female mice aged 29 to 33 weeks (mean age 31 weeks) were 
treated with tilorone, 100 mg/kg, given once weekly by gavage. All three groups of 
mice were treated until death. Blood was collected from the orbital plexus before 
treatment began and after 12 and 24 weeks of treatment. In most instances, 
moribund animals were bled before they were autopsied. At each bleeding, white 
blood cells (WBC) were counted in the conventional manner and thin blood films 
were prepared. Differential counts of 100 leukocytes on each slide were per- 
formed. Sera for ANA tests, anti-DNA determinations, and complement assays 
were stored in sealed capillary tubes at -20°C. 
Histology 
Complete autopsies were done routinely following a protocol described in an 
earlier publication (5), and tissues were examined by light microscopy for any 
pathologic process that might have contributed to death. Fibrinoid necrosis of 
arteries in any organ was recorded. Cross sections through both thymic lobes 
were examined. An eyepiece micrometer was used to measure widths of thymic 
medulla and thymic cortex, and cortical:medullary (C:M) width ratios were calcu- 
lated. Complete cortical atrophy was identified when the cortex was shrunken and 
depleted of lymphocytes. Fibrosis in each thymus was assessed in Camoy-fixed 
tissue stained by van Gieson’s method. Histologic abnormalities in 20 glomeruli in 
each section of renal tissue were counted using a quantitative method adapted for 
use in this laboratory (6). 
Autoantibodies 
Autoimmune responses were evaluated by measuring heterogeneous ANA in 
titered mouse serum using an indirect immunofluorescent technique (7). Specific 
anti-double-stranded-DNA antibodies were quantitated by an adaptation of the 
Farr technique, using KB-cell-derived 14C-labeled DNA as substrate (7). 
Complement 
Serum levels of the third component of complement (C,) were determined by 
single radial immunodiffusion of 0.002 ml of serum in 1% agar containing 0.005 M 
EDTA and 5% antiserum (Cappel Laboratories, Downingtown, Pa.). The an- 
tiserum was raised in rabbits inoculated with zymosan-mouse complement com- 
plex according to the method of Mardiney and Miiller-Eberhard (8). Separate 
immunoelectrophoretic analyses in 0.005 M EDTA agar of fresh cold EDTA- 
treated mouse plasma and mouse serum stored 18 hr at room temperature showed 
that the antiserum detected both /3 lc- and &,-globulins. Although the antiserum 
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reacted with C, and at least one of its breakdown products, this determination will 
be referred to as a test for C,. A pool of serum from healthy outbred albino mice 
(Spartan Co., Haslett, Mich.) was assigned a value of 100 C:, units/O.002 ml, and 
four dilutions of this reference serum were included on each diffusion plate. After 
incubation at room temperature for 72 hr, the diameters of precipitin rings formed 
by the reference serum plotted against individual dilutions of the same serum 
formed straight lines on a semilog graph. Serum C:, levels in individual mice were 
read from these standard curves and expressed in arbitrary C, units. Percentage 
coefficient of variation (C) was calculated to determine the reproducibility of 
precipitin ring diameters produced by each dilution of reference serum on 38 
individual diffusion plates. For serum diluted 1:8, C = 4.8%; for I : 16, C = 4.5%; 
for 1:32, C = 5.0%; for 1:64. C = 6.2%‘. 
Itlterferon 
Because tilorone-induced interferon activity varies in different strains of mice 
(9), a pilot study was performed to detect interferon in NZB/NZW mouse serum. 
Thirty-four 4-month-old female NZB/NZW mice were given tilorone, 100 mg/kg, 
by gavage. Interferon activity assayed by a standard test-tube method (10) was 
present in pooled serum samples obtained 16 and 24 hr after treatment. Control 
mice and young tilorone-treated mice in the current study were tested at the 
intervals listed in Table 3. The microassay described by Dahl and Degre (11) was 
adapted to test this serum for interferon activity on mouse L-929 cells in individual 
wells of Micro Test II tissue culture plates (Falcon Plastics, Oxnard, Calif.). The 
result of each test was expressed as the reciprocal of the PD,,, the dilution of test 
serum that protected 50% of cells from viral cytopathogenic effect (CPE). The 
TCD,, (tissue culture dose of virus that destroyed 50% of cells) was determined by 
back titration on each individual plate. The challenge dose of VSV virus used on 
each plate ranged from 56 to 170 TCD,,. In each determination, pooled standard 
serum with a high level of antiviral activity from a separate group of tilorone- 
treated mice was included as a positive control. Plain medium was used as a 
negative control. 
Statistical Andysis 
x’ calculations and student’s t tests were performed using the MIDAS software 
package (12) within the MTS system on the AMDAHL 47OV/6 computer. 
Mortalit? 
RESULTS 
Figure 1 illustrates cumulative deaths in control and treated mice. In accord 
with earlier studies in this laboratory (5), control mice began to die with renal 
disease and vasculitis at 27 weeks of age. The mean age at death was 45 weeks; the 
oldest survivor died at 77 weeks of age. An unexpected finding was the acceler- 
ated death rate in young mice treated with tilorone. The first death in this treat- 
ment group occurred in a 24-week-old female mouse, 8 weeks after tilorone 
therapy began. The mean age at death in young treated mice was 35 weeks; the 
oldest surviving mouse died at the age of 60 weeks. When the shortened mean 
lifespan in young treated mice was compared with the lifespan in control mice, the 
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difference was significant (P = 0.047). Postmortem examinations showed that 13 
young treated mice died with accelerated renal and vascular disease. Two animals 
were found autolyzed, and the causes of death could not be determined. Tilorone 
therapy had no effect on mice in the older treatment group (Fig. 1). In these 
animals, the mean age at death was the same as that of control mice (45 weeks). 
Nine old treated mice died with renal disease and arteritis. Two animals died with 
hemorrhage, and one mouse had a large uterine abscess and widespread 
amyloidosis. Despite daily surveillance for evidence of illness, two old mice died 
unexpectedly and were autolyzed. Early autolysis in four autopsied mice in this 
group prevented detailed evaluation of their thymic and renal histologies. Two 
control mice and one old treated mouse died when ether anesthesia was given 
before a routine bleeding. These three iatrogenic deaths were omitted from 
longevity data and the graph in Fig. 1. 
Histologic Abnormalities 
The most notable anatomic lesions were found in thymic tissue, kidneys, and 
arteries. In untreated animals, the mean C:M ratio was 0.92 (2 0.14 SE). Com- 
plete cortical atrophy was found in one control mouse. In young tilorone-treated 
mice, cortical thinning was common and the mean C:M ratio was 0.58 (+ 0.16). In 
4 of the 13 thymus glands examined in this group, the cortical areas were com- 
pletely atrophic. Thymic cortical atrophy was most severe in the older treated 
female mice. The mean C:M ratio was 0.22 (& 0.09). Compared to control animals, 
this value was significant (P = 0.002). Three of nine thymus glands from old 
treated mice had acellular cortices. When van Gieson-stained sections of thymus 
were examined, excessive fibrous tissue was not identified in the cortical areas. 
Loss of lymphocytes, rather than cortical fibrosis, caused atrophy of the thymic 
cortex. An increased amount of fibrous tissue surrounded blood vessels in the 
thymic medulla in 5 of 12 control mice, in 8 of 13 young treated mice, and in 4 of 9 
old treated mice. 
Every control and treated animal had severe glomerulonephritis that was 
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FIG. 1. Cumulative deaths are illustrated in young and old female NZB/NZW mice treated with 
tilorone, 100 mg/kg/week, until death. Control mice received water. Mean lifespan in young treated 
mice was shortened significantly compared to control mice (P = 0.047). 
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characteristic of NZB/NZW renal disease (5). Thickening and hypercellularity of 
the mesangial stalk, glomerular hypercellularity, thickening of the glomerular 
basement membrane, and crescent formation were found in kidney tissue from 
each animal. In many instances, abundant librinoid change was found in the 
glomeruli. Control mice (mean glomerular lesion count, 53 ? 2) and young treated 
mice (mean lesion count 50 + 2) had severe renal disease. In old treated mice, the 
mean lesion count was 38 ? 3. The unexpected decrease in severity of glomerular 
disease in old mice may have reflected loss of diseased renal tissue in six au- 
tolyzed mice. Generalized arteritis was common. Fibrinoid necrosis of small and 
medium arteries was present in kidneys and lymphoid organs (spleen, lymph 
nodes, and thymus) in 9 of 13 control mice. Widespread arteritis was present in 11 
of 13 young treated female mice. In old treated mice, arteritis was found in five of 
nine animals with complete autopsies. 
Autountibodies and Complement 
In control NZB/NZW mice, median titered ANA values increased from 0 to 7 in 
the first 24 weeks of this study (Table I). A similar increase in ANA titers was 
observed in young treated mice. Mean anti-DNA levels in untreated mice showed 
an age-dependent increase from 16 to 38% in the first 24 weeks of observation; 
mean anti-DNA values in young treated mice increased from 16 to 27%. Autoanti- 
body levels in old treated mice were not included in Table 1 because these values 
TABLE 1 
AUTOANTIBODIES AND C, LEVELS IN TILORONE-TRE.~TED .WD CONT.ROI. M~cr 
Weeks of treatment 
Mice 0 12 ‘4 Terminal 
ANA” 
Control o(o-5) 5(0-7) 7(3-9) 5( l-9) 
[ISI [ISI [I II 1121 
Young treated 0(0-S) 3(0-7) 7(3-II) 3(0- I I) 
[I51 I131 [61 [121 
Anti-DNA” 
Control 16 k 0.6 24 t 3 38 i 5 21 i I 
Young treated 16 + 0.6 20 t 2 27 t 4 19 f 1 
C:; 
Control IZOt 7 68 + 7 70 + 9 104 f 17 
Young treated 116 + 16 89 + 15 63 2 10 55” 2 8 
” Median (range). Values are expressed as the highest tube number (l-log, of serum dilution) giving 
a positive test for heterogeneous ANA using an indirect immunofluorescent technique. Brackets en- 
close the number of mice tested at each bleeding. 
b Mean * SE. A modification of the Farr technique was used to test sera for specific antibodies to 
double-stranded DNA. Values are expressed as percentage of r4C-labeled DNA bound to 0.015 ml of 
mouse serum. 
r Mean 2 SE. Serum C, levels were determined by radial immunodiffusion. Values were expressed 
as arbitrary C, units, determined by comparing precipitin ring diameters produced by NZBiNZW 
sera with diameters produced by twofold dilutions of standard mouse serum. 
d Compared to control mice, P = 0.005. 
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were not directly comparable to control values. At the beginning of the study, 
ANA titers and anti-DNA levels reflected active autoimmune disease in these 
older animals. The median ANA titer increased from 5 (range O-9) before treat- 
ment to 9 (range 5-11) after 12 weeks of treatment. The terminal median ANA 
titer was 7 (range 5-9). Mean anti-DNA levels in old treated mice increased from 
the mean pretreatment level of 33 ? 4% to 46 + 2% after 12 weeks of therapy. The 
mean anti-DNA value in terminal serum was 23 + 2%. In accord with the report of 
Miller and associates (13), C, decreased with age in unmanipulated female NZBi 
NZW mice (Table 1). In control mice, mean C, levels fell from 120 to 70 units 
during the first 24 weeks of the study. C, values in young treated mice were similar 
to values in control animals. In terminal serum, the mean C, level in young treated 
mice (55) was reduced significantly compared to the mean level in untreated 
control mice (104); P = 0.005. C, levels assayed in old treated mice were consis- 
tently lower than C, levels in the reference mouse serum used as a standard on 
each immunodiffusion plate. Mean C, levels in the older mice were 62 (& 12) 
before treatment and 86 (2 17) after 12 weeks of treatment. The mean terminal C, 
value in this group was 92 (? 22). 
Leukocyte Counts 
During the course of this study, mean total WBC counts fell in treated and 
control mice. Peripheral circulating large and medium lymphocytes (LML) de- 
creased throughout the treatment period, and mean absolute counts of these cells 
did not differ significantly from cell counts in control mice (Table 2). Twelve weeks 
after the study began, the mean small lymphocyte (SL) count of 656 in young 
treated mice was significantly smaller than the corresponding mean SL count of 
1152 in control mice (P = 0.03). When terminal peripheral blood smears were 
examined, mean numbers of SL were 197 in control mice and 787 in young treated 
female mice. This difference was significant at the 0.02 level. In old treated female 
mice, there were no appreciable changes in mean absolute WBC, SL, or LML 
counts in the first 12 weeks of the study. Terminal cell counts in the older mice 
were almost identical to terminal cell counts in control mice. Despite a careful 
TABLE 2 
PERIPHERAL CIRCULATING LEUKOCYTES (WBC), SMALL LYMPHOCYTES (SL), AND LARGE AND 
MEDIUM LYMPHOCYTES (LML) IN TIORONE-TREATED AND CONTROL MICE 
Weeks of treatment 
Mice 
0 12 24 Terminal 
WBC SL LML WBC SL LML WBC SL LML WBC SL LML 
Control 6765 701 5201 5091 1152 3288 3840 306 2580 3376 197 1654 
+308” +118 t247 +510 -cl75 ~372 +395 ?44 5302 -c552 258 *223 
Young treated 55 12 631 4327 3852 656b 2659 4047 376 2740 5154 787’ 2546 
2573 ,82 ?483 ?456 tl18 +310 ?272 ?88 +268 2713 ?216 ?478 
” Mean absolute cell count (ceils/mm3) 2 SE. 
b Compared to control mice, P = 0.03. 
r Compared to control mice, P = 0.02. 
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search for morphological abnormalities, no granules or vacuoles were noted in 
cytoplasm of mononuclear cells. 
Interferon Assays 
After a prolonged course of treatment. NZB/NZW mice were not refractory to 
the interferon-inducing properties of tilorone. Table 3 describes interferon activity 
in control and young treated mice tested 24 and 32 weeks after treatment began. In 
accord with the findings of De Clercq and Merigan (14), the greatest serum interfe- 
ron activity was found 16 hr after tilorone was administered. 
DISCUSSION 
Other investigators have attempted to control infection with C-type virus and 
suppress autoimmune disease in New Zealand mice by administering antiviral 
drugs to these animals. Gabriel (15) treated NZB/NZW mice with methisazone 
(1 -methylsantin 3-thiosemicarbazone), a compound that directly inhibits multipli- 
cation of RNA and DNA viruses (16). The mean lifespan was 10.6 months in the 
treated mice, compared to a mean lifespan of 9 months in a group of control mice. 
This evidence that a viral inhibitor might prevent early deaths in autoimmune 
NZB/NZW mice was supported by data from another study employing therapy 
with an interferon inducer. Lambert and Dixon (17) treated a group of female 
NZB/NZW mice with Statolon, a double-stranded natural RNA (18). Although 
ANA appeared spontaneously, ANA titers were decreased in treated mice com- 
pared to control mice after 4 months and 7 months of therapy. Steinberg et al. (19) 
administered a synthetic double-stranded RNA, polyinosinic-polycytidilic acid 
(poly I-poly C), to hybrid New Zealand mice. Although recipient female mice 
produced interferon, they developed anti-poly I-poly C antibodies, high levels of 
anti-DNA, and severe renal disease. This experiment showed that a ribonu- 
Mice 
Total Time after Serum 
duration of oral dose of interferon 
N” therapy (weeks) tilorone (hrs) tite+ 
Control 6 24 16 
Young treated 3 24 16 
Control 5 32 0 
16 



























“N = Number of mice tested at each interval. 
ti Pooled serum from mice in each group was tested for ability to protect mouse L-929 cells from 
bovine VSV-induced CPE using a microassay technique. Test results were expressed as the reciprocal 
of the PD,, (the dilution of test serum that protected 50% of cells from CPE). 
’ Twofold dilutions of pooled standard serum from a separate group of tilorone-treated mice were 
included on each microtiter plate as a positive control. 
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cleotide compound used as an inducer of interferon could act as an antigen, 
stimulating autoantibody formation and accelerating disease in NZB/NZW mice. 
In the current study, it was anticipated that using tilorone as an interferon 
inducer would avoid the stimulation of autoantibody formation observed in New 
Zealand mice treated with poly I-poly C. Interferon activity was detected in sera 
from young treated mice, but these animals were not protected from autoimmune 
disease. Autoantibodies appeared spontaneously and increased with advancing 
age in control and tilorone-treated mice. C, levels decreased with age, reflecting 
increasing severity of immune-complex disease (13). Postmortem examinations 
confirmed that treated and control mice died with glomerulonephritis and arteritis. 
Two important observations suggested that continuous tilorone therapy beginning 
at an early age had an adverse effect on disease in young female NZB/NZW mice. 
First, lifespans were decreased significantly in the young treatment group com- 
pared to the control group. In addition, C, levels in terminal sera from young 
treated mice were lower than mean C, levels in dying control mice. In old treated 
mice, lifespans were not influenced by tilorone therapy. This finding suggested 
that the course of established disease in older animals was not influenced by 
tilorone-induced changes in immune response. 
The immune system is defective in NZB/NZW mice; their thymic-regulated, 
cell-mediated immunity is depressed. Thymic suppressor cells may be destroyed 
spontaneously in adult New Zealand mice, and it has been postulated that loss of 
thymic suppression accelerates production of autoantibodies in these animals (20). 
Recently, tilorone was found to influence immune responses in rodents, and the 
immunoregulatory effects of this drug may explain the shortened lifespan in young 
treated NZB/NZW mice. Megel and co-workers (21) reported that tilorone 
therapy enhanced immune responses to sheep red blood cells in mice. In contrast 
to the apparent stimulation of humoral immunity, treatment with tilorone sup- 
pressed cell-mediated immunity in rats. Depletion of thymic-dependent cells may 
be the mechanism whereby tilorone therapy influences immune responses. Trans- 
ient disappearance of circulating thymic-dependent lymphocytes has been de- 
scribed in mice threated with tilorone (22). Long-term administration of tilorone to 
young NZB/NZW mice may have caused premature loss of suppressor thymic 
function, thereby accelerating autoimmune disease and causing early death. 
In the current study, treated mice commonly lost thymic cortical cells. These 
changes may have reflected stress-induced cortical atrophy in chronically ill ani- 
mals (23). Nevertheless, other investigators have described transient loss of cells 
in thymic-dependent areas of spleen, lymph nodes, and Peyer’s patches in mice 
and rats treated with a single dose of tilorone (24). It may be postulated that 
repeated doses of tilorone given once a week over a period of months had a more 
pronounced effect on the thymus than one dose, and prolonged treatment may 
have caused irreversible atrophy of the thymic cortex in NZB/NZW mice. 
Although the experimental findings suggested that tilorone destroyed or 
mobilized lymphoid cells in thymic tissue, there was no evidence that long-term 
therapy with the drug consistently influenced numbers of peripheral lymphocytes. 
Twelve weeks after the study began, the mean SL count in young treated mice 
was decreased significantly compared to that of control mice. When testing was 
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repeated 12 weeks later, SL counts in treated mice were similar to those of 
controls. The mean terminal SL count of 787 in young treated mice was greater 
than the SL count of 197 in terminal blood smears from control mice (P = 0.02). 
Fluctuation of peripheral lymphocyte counts may be partially explained by our 
practice of bleeding mice 24 to 72 hr after the weekly dose of tilorone was adminis- 
tered. In “normal” experimental animals without autoimmune disease, oral 
tilorone was found to produce peripheral lymphocytopenia lasting 48 hr (22). 
Based upon the work of Rohovsky et al. (25). it was anticipated that granules 
and vacuoles would be observed in the cytoplasm of mononuclear cells from 
treated mice. However, these morphologic changes were not found in WBC from 
the hybrid New Zealand mice in this study. This observation should stimulate 
further investigation into the relationship between tilorone-induced cytoplasmic 
lesions and functional classification of lymphoid cells. If granules and vacuoles 
were markers of thymic-dependent lymphocytes, the absence of such markers in 
tilorone-treated NZB/NZW mice might reflect a specific decrease in numbers of 
circulating thymic-dependent cells. 
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